Implementing an electronic end-of-life chemotherapy utilization measure Published March 2020 Citation Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, and Meropol NJ. . Journal of Oncology Practice. . http://ascopubs.org/doi/abs/10.1200/JOP.18.00408 Authors:Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, and Meropol NJ Sources:Journal of Oncology Practice Share Posted inPublicationsTreatment patterns More publicationsASCO Annual MeetingMay 2026Real-world treatment patterns and outcomes among patients with high-risk and very high-risk non-metastatic prostate cancerHankinson EA, Qian Y, Ward P, Patel K, Dolor A, Sujenthiran A.Publication summaryPublicationsTreatment patternsProstate cancerASCO Annual MeetingMay 2026Real-world second-line treatment patterns and outcomes by platinum sensitivity in extensive-stage small cell lung cancer in the post-immunotherapy eraRinaldi C, Reiss S, Collins J, Schwed K, Chiu M, Castellanos E.Publication summaryPublicationsTreatment patternsSmall cell lung cancerBlood NeoplasiaApril 2026Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimensPrescott J, Parrinello C, Sawas A, et al.Publication summaryPublicationsTreatment patternsChronic lymphocytic leukemia